For more information on our site, make sure to read our Privacy Policy.

Monday, December 3, 2012

A Key Biological Mechanism in Multiple Sclerosis Has Been Identified by Scientists

A Key Biological Mechanism in Multiple Sclerosis Has Been Identified by Scientists

A key underlying process implicated in multiple sclerosis (MS) – a disease that causes progressive and irreversible damage to nerve cells in the brain and spinal cord, has been defined for the first time by scientists at the Gladstone Institutes. The discovery offers new hope for the people who suffer from MS, a debilitating disease for which there is no cure.

Using animal models the researchers in the laboratory of Gladstone Investigator Katerina Akassogiou, PhD, have identified precisely how a protein that seeps from the blood into the brain sets of a response that, over time, causes the nerve cell damage that is a key indicator of MS. Reporting these findings in the latest issue of Nature Communications, the groundwork was laid for much-needed therapies to treat MS.

MS develops when the body's immune system attacks the brain, afflicting more than two million people worldwide.The attacks from MS lead to a host of symptoms including numbness, fatigue, difficulty walking, paralysis and loss of vision. Some of these symptoms may be delayed with drug therapies, but they do not treat the disease's underlying cause-which is just beginning to be understood by researchers.

"To successfully treat MS, we must first identify what triggers the disease and what enables its progression," said Dr. Akassoglou, who also directs the Gladstone Center for In Vivo Imaging Research and is a professor of neurology at the University of California, San Francisco, with which Gladstone is affiliated. "Here, we have shown that the leakage of blood in the brain acts as an early trigger that sets off the brain's inflammatory response—creating a neurotoxic environment that damages nerve cells."
Dr. Akassogiou and her team were able to reach this conclusion by monitoring the disease's progression in the brain and spinal cord of mice modified to mimic the signs of MS by using advanced imaging techniques. Traditional techniques only show “snapshots” of the disease's pathology. However, this analysis allows researchers to study individual cells within the living brain—and to monitor in real-time what happens to these cells as the disease worsens over time.

"In vivo imaging analysis let us observe in real-time which molecules crossed the blood-brain barrier," said Dimitrios Davalos, PhD, Gladstone staff research scientist, associate director of the imaging center and the paper's lead author. "Importantly, this analysis helped us identify the protein fibrinogen as the key culprit in MS, by demonstrating how its entry into the brain through leaky blood vessels impacted the health of individual nerve cells."

A blood protein that is involved in coagulation, fibrinogen, is not found in the healthy brain. However, it is revealed in vivo imaging over different stages of disease that a disruption in the blood-brain barrier allows blood proteins—and specifically fibrinogen—to seep into the brain. A rapid response to fibrinogen's arrival is initiated by microglia—immune cells that act as the brain's first line of defense. They release large amounts of chemically reactive molecules called 'reactive oxygen species.' A toxic environment is created within the brain by this, which damages nerve cells eventually leading to the debilitating symptoms of MS.

By genetically modifying fibrinogen in the animal models, an important strategy to halt this process was found. Without affecting fibrinogen's essential role as a blood coagulant, this strategy was able to disrupt the protein's interaction with microglia. Microglia did not react to fibrinogen's arrival in these models, and did not crate a toxic environment. The mice failed to show the type of progressive nerve cell damage seen in MS as a result.

"Dr. Akassoglou's work reveals a novel target for treating MS—which might protect nerve cells and allow early intervention in the disease process," said Ursula Utz, PhD, MBA, a program director at The National Institutes of Health's National Institute of Neurological Disorders and Stroke, which provided funding for this research.
"Indeed, targeting the fibrinogen-microglia interactions to halt nerve-cell damage could be a new therapeutic strategy," said Dr. Akassoglou. "At present we are working to develop new approaches that specifically target the damaging effects of fibrinogen in the brain. We also continue to use in vivo imaging techniques to further enhance our understanding of what triggers the initiation and progression of MS. "

Source: Science Codex (30/11/12)

Original Story: Scientists identify key biological mechanism in multiple sclerosis Sclerosis Resource Centre

Author: William D.

Thursday, November 29, 2012

Important News - In Need of Doctors

We need a big favor at the moment, can you help? I hope so. Our group has finally reach 1,000+ Fans and 800+ visitors on our blog, so it's time I start our official website. In this website we will have a lot of information about Multiple Sclerosis, very detailed too. For example, we will have a page all about Myelin and another page about teriflunomide, and so on. It will contain all kinds of information and we will try to make it the main source for answers for those with multiple sclerosis or care takers. This project will take more than 2 years to make it by myself and that is why I need your help.

 I only ask that if you know any doctors that are specialized in multiple sclerosis and you know their email that you will let us know so we can ask them to help us make our website. When I say "help," I mean let them explain to our visitors what the subject (ex. myelin) is about and how it affects multiple sclerosis patients or what it has to do with multiple sclerosis, and so on. They will be given FULL credit on their work and we will take no credit for their work, absolutely guaranteed. We are only trying to raise awareness, and to help those with multiple sclerosis.

  You can email us their email at: and/or 

If you are a doctor and you can help, please contact us. 

 ***Please share this post to help us build up our website***

Our website can be found at (Under Construction)

Find us on Facebook

Tuesday, November 27, 2012

Genzyme’s Once-Daily, Oral AUBAGIO® Approved in Australia for Treatment of Relapsing Multiple Sclerosis

A new drug has been approved by the Australian Therapeutic Goods Administration (TGA). This new drug is known as Aubagio (teriflunomide) 14 mg. Aubagio is a once-daily, oral treatment for relapsing remitting forms of multiple sclerosis.


The drug company Genzyme launched a major campaign aimed to get their new drug to be prescribed free of charge to patients with relapsing remitting multiple sclerosis (RRMS).

Each neurologist that is participating in this campaign will be able to sign up 10 patients for Aubagio, the once-daily drug.

This new drug is a powerful, but yet it's also a dangerous drug. Since Teriflunomide is such a powerful drug, it has a big gap full of serious side-effects.
“I would not trust information given by the drug company but would wait for independent assessments,” Dr Vitry told Neurology Update’s
Not only is teriflunomide a powerful and dangerous drug, it has been found that it could remain in your body for up to two years and may cause birth defects and liver damage.

Gabriel D. - Contact | Facebook

Reference: MSRC - Genzyme blitzes Australian MS market with free oral drug teriflunomide
               Neurology Update (27/11/12)